Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 9/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PROKR2 | Q8NFJ6 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752475 | 0.88 | PROKR1 (0.48) | F10MAPTPROKR1KLKB1TP53 | |
| SCHEMBL2635865 | 0.84 | PROKR1 (0.45) | MAPTPROKR1PROKR2 | |
| SCHEMBL8505365 | 0.82 | PROKR1 (0.42) | MAPTPROKR1PROKR2 | |
| SCHEMBL5175180 | 0.81 | PROKR1 (0.42) | PROKR1PROKR2 | |
| SCHEMBL8515109 | 0.81 | PROKR1 (0.42) | MAPTPROKR1GAAPROKR2 | |
| SCHEMBL5427195 | 0.81 | PROKR1 (0.48) | MAPTPROKR1PROKR2 | |
| SCHEMBL12059847 | 0.80 | PROKR1 (0.49) | MAPTPROKR1SMN1; SMN2PROKR2 | |
| SCHEMBL13801523 | 0.78 | ALDH1A1 (0.48) | MAPTGAASMN1; SMN2 | |
| SCHEMBL2635634 | 0.78 | CCR2 (0.58) | MAPT | |
| SCHEMBL10267964 | 0.78 | RGS4 (0.42) | PROKR1TP53PROKR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866290-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-01 | — | — | EP | disclosed |
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012006003-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| US-20110319418-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-7968710-B2 | Gastrointestinal disorders;inflammatory bowel disorders; gastroesophageal reflux; constipation | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | F10 2567/4885MAPT 4073/4885PROKR1 2/4885 |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | F10 2183/4885MAPT 4202/4885PROKR1 1/4885 |
| US-20110319418-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | F10 1282/4885MAPT 4418/4885PROKR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.